Business Wire

Sutherland Announces Enterprise-Ready Agentic AI Delivering Real-World Business Outcomes

29.7.2025 14:00:00 CEST | Business Wire | Press Release

Share

Sutherland, a global leader in business and digital transformation, is redefining what’s possible when people and AI work together. Its Agentic AI solutions are now powering smarter, more efficient operations for some of the world’s leading brands. Modular, flexible, and designed to scale, Sutherland’s Agentic AI goes beyond task automation to solve real business problems. By combining human judgment with intelligent automation, Sutherland is helping organizations create secure and adaptable digital experiences that are built to last.

These deployments are already driving real results for tier-1 media and telecom enterprises, showcasing some of the most advanced, real-world uses of Agentic AI today.As businesses face mounting pressure to cut costs, protect sensitive data, and elevate customer experiences in real time – without expanding headcount – Sutherland provides a clear path forward.

Its enterprise-ready platform brings together a dynamic network of specialized AI agents that flex with the needs of the business. These agents handle everything from real-time translation and fraud detection to post-interaction analysis and automated coaching. As a result, organizations can move faster and deliver better outcomes without compromise.

“Our vision for Agentic AI is rooted in collaboration – not just automation,” said Doug Gilbert, Chief Information Officer and Chief Digital Officer at Sutherland. “We have engineered intelligent agents that think, learn, and evolve alongside humans to solve the most complex business challenges – from regulatory compliance to dynamic customer support. This is where digital transformation gets real.”

Real-World Impact: From Streaming to Telecom

Global Streaming Leader Elevates Customer Experience with AI-Powered Collaboration

A leading global streaming platform chose Sutherland’s Agentic AI to improve both digital and human-led customer interactions. The AI teams up with live agents in real time, analyzing questions on the spot and pulling the most relevant answers from a vast knowledge base. It actively suggests responses, summarizes calls, and recommends subscription upgrades – learning and improving with every interaction, thanks to ongoing human feedback. The result? Faster support and a smoother, more satisfying experience for both customers and agents.

Other key outcomes include:

  • 35% reduction in average handle time, 6% boost in accuracy
  • Automatically summarizing documents to provide real-time support
  • Intelligently directing customers and seamlessly switching between AI and human agents
  • Ongoing coaching through live performance reviews and feedback
  • Personalized customer recommendations, like AI-suggested subscription upgrades, helping customers save up to 15%

U.S. Telecom Leader Protects Customer Data and Stays Compliant, Without Rewriting a Single Line of Code

When stricter FCC regulations demanded better protection for sensitive customer data, a top 3 U.S. telecom provider turned to Sutherland’s Agentic AI to meet the challenge. The solution was rolled out rapidly across 27 legacy systems and 126,000 agents – seamlessly, without disrupting daily operations.

Sutherland’s PCI-compliant AI agents automatically detect and remove sensitive data from voice calls, chats, transcripts, and screen recordings in real time. No rewrites. No delays. Just reliable, scalable protection.

Beyond compliance, the platform helps the telecom giant:

  • Detect fraud as it happens and securely process payments
  • Analyze interactions post-call with built-in audit trails
  • Unite all communication channels – voice, email, chat, social, and SMS – on a single recording platform

Today, Sutherland’s Agentic AI is driving real results across highly regulated industries – from media and telecom to healthcare and logistics. By blending powerful AI platforms with automation and human insight, Sutherland is helping businesses stay compliant and create meaningful, lasting change.

About Sutherland

Artificial Intelligence. Automation. Cloud Engineering. Advanced Analytics.

For Enterprises, these are key factors of success. For us, they’re our core expertise.

We work with global iconic brands. We bring them a unique value proposition through market-leading technologies and business process excellence. At the heart of it all is Digital Engineering - the foundation that powers rapid innovation and scalable business transformation.

We’ve created over 200 unique inventions under several patents across AI and other emerging technologies. Leveraging our advanced products and platforms, we drive digital transformation at scale, optimize critical business operations, reinvent experiences, and pioneer new solutions, all provided through a seamless "as-a-service" model.

For each company, we provide new keys for their businesses, the people they work with, and the customers they serve. With proven strategies and agile execution, we don’t just enable change - we engineer digital outcomes.

Sutherland
digital outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250729497244/en/

Contacts

For further queries: mediarelations@sutherlandglobal.com
Know more: www.sutherlandglobal.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sutherlandg
lobal.com%2F&esheet=54297688&newsitemid=20250729497244&lan=en-US&anchor=www.suth
erlandglobal.com&index=3&md5=8f04344388883ef96cba2cfa1f2ef04f

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye